CDMOs Expand and Build for Future Growth
A roundup of recent expansion and AI initiatives by CDMOs highlights Fujifilm Biotechnologies and Lonza. Fujifilm’s Holly Springs QC lab began operations in May, supporting increased batch/testing capacity, and it plans to add bioreactors by 2028, including a second-phase drug-substance deal with argenx for Vyvgart products. Lonza is building AI talent and expanding Swiss sites for ADC and HPAPI capacity, while selling CHI for CHF 2.3B.






